CanBas Co., Ltd., a Japanese bio-pharmaceutical company dedicated to developing innovative cancer fighting drugs, has received the approval from the U.S. Food and Drug Administration, granting its drug orphan status.
The companyâ€™s leading drug, CBP501, enhances the effectiveness of the chemotherapy drug Cisplatin, a treatment for malignant pleural mesothelioma. Mesothelioma is a rare cancer linked to asbestos exposure which affects the lungs, heart and chest cavity. There is currently no cure for the disease but the researchers hope to change that with their new drug.
CanBas has announced that the US FDA has granted orphan drug status this month to CBP501 for the treatment of malignant mesothelioma. The means that the pharmaceutical company can now qualify for financial incentives to develop more drugs to treat rare diseases like mesothelioma.
The incentives are vital in the development of the treatments because drug companies have a hard time justifying the amount of time and resources necessary to market drugs that only have a limited demand and which therefore generate little profit.
A trial study comparing the results of patients with advanced malignant pleural mesothelioma in the U.S., Russia and Argentina that have been treated with Cisplatin and Pemetrexed both with and without CBP501 is currently underway.
Unfortunately, mesothelioma is one of the most difficult diseases to both diagnose and treat. It can take up to 50 years for the cancer to develop and usually by the time it does, itâ€™s too late for the victim to seek help.
If you or a loved one are struggling with mesothelioma or were exposed to asbestos, turn to a top mesothelioma lawyer immediately to file a claim. As an asbestos victim, you may be entitled to thousands or even millions of dollars in money damages and medical care, and mesothelioma attorneys will fight for your rights to ensure you obtain the full spectrum of benefits you deserve.